At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
LME636 60 mg/mL ophthalmic solution +2 moredrug
Likely dose
LME636 60 mg/mL ophthalmic solutionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Safety and Efficacy of LME636 in Patients With Acute Anterior Uveitis
In Brief
A Phase 2 clinical trial evaluating LME636 60 mg/mL ophthalmic solution, Dexamethasone 0.1% ophthalmic solution, and 1 other intervention for Acute Anterior Uveitis. Completed, enrolled 45 participants.
Detailed Summary
The purpose of the study is to determine whether topical ocular administration of LME636 60 mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC) associated with acute anterior uveitis (AAU).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Anterior Uveitis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionMar 2016
TodayJul 2026
First PostedJun 26, 2015
Enrollment StartJul 17, 2015
Primary CompletionMar 21, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.0 years ago
Interventions
LME636 60 mg/mL ophthalmic solutiondrug
Dexamethasone 0.1% ophthalmic solutiondrug
LME636 Vehicledrug
Inactive ingredients used for masking purposes